|
Study
|
DIPOL
|
AVID
|
RESIST
|
TULIP
|
OPTICUS
|
Total
|
|---|
| |
IVUS
|
QCA
|
IVUS
|
QCA
|
IVUS
|
QCA
|
IVUS
|
QCA
|
IVUS
|
QCA
|
IVUS
|
QCA
|
|---|
|
Patients, n
|
83
|
80
|
369
|
375
|
79
|
76
|
73
|
71
|
273
|
275
|
877
|
877
|
|
Death, n (%)
|
1 (1.2)
|
1 (1.3)
|
12 (3.3)
|
7 (1.9)
|
1 (1.3)
|
1 (1.3)
|
2 (2.7)
|
1 (1.4)
|
5 (1.8)
|
1 (0.36)
|
21 (2.4)
|
11 (1.3)
|
|
Nonfatal MI, n (%)
|
1 (1.2)
|
4 (5)
|
25 (6.8)
|
19 (5.1)
|
N/A
|
N/A
|
1 (1.4)
|
5 (7.0)
|
6 (2.2)
|
10 (3.6)
|
33 (4.1) 1
|
38 (4.7) 1
|
|
MACE, n (%)
|
6 (7.2)
|
13 (16.2)
|
68 (18.4)
|
70 (18.7)
|
20 (25.3)
|
28 (36.8)
|
9 (12.3)
|
19 (26.8)
|
49 (17.9)
|
42 (15.3)
|
152 (17.3)
|
172 (19.6)
|
-
*The analysis of nonfatal MI excludes the RESIST Study, where this outcome was not calculated. MI, myocardial infarction; MACE, major adverse cardiovascular events; IVUS, interventional ultrasound.
